DFTX:NASDAQ
Definium Therapeutics Inc
$43.08
arrow_upward
+5.30%(+2.17) 1D
Aug 12, 2:42:27 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DFTX...
Open
$47.51
High
$47.55
Low
$42.42
Mkt. cap
5.79B
Avg. vol.
2.08M
Volume
6.19M
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
Open
$47.51
High
$47.55
Low
$42.42
Mkt. cap
5.79B
Avg. vol.
2.08M
Volume
6.19M
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
News stories
From web sources and news partners
Yahoo Finance
·
1 hour ago
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’
MarketBeat
·
2 hours ago
Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up - What's Next?
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorPharmaceutical industry
Websitedefiniumtx.com
Analyst ratings
Based on 14 analysts giving stock ratings to DFTX in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for DFTX in the last 3 months.
Highest
Current $43.08
$75.00 (+74.09%)
Average
$62.29 (+44.59%)
Lowest
$50.00 (+16.06%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ami Fadia Needham | Buy | Maintained | $50.00 | +16.1% | 08/12/2026 |
Francois Brisebois LifeSci Capital | Buy | Reiterated | $75.00 | +74.1% | 08/12/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $70.00 | +62.5% | 08/11/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $53.00 | +23% | 08/10/2026 |
Justin Walsh JonesTrading | Buy | Reiterated | $74.00 | +71.8% | 08/07/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $65.00 | +50.9% | 08/07/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $60.00 | +39.3% | 08/07/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $58.00 | +34.6% | 08/07/2026 |
Paul Matteis Stifel Nicolaus | Buy | Reiterated | $60.00 | +39.3% | 08/07/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $75.00 | +74.1% | 08/07/2026 |
Brian Abrahams RBC Capital | Buy | Maintained | $57.00 | +32.3% | 08/06/2026 |
Benjamin Burnett Wells Fargo | Buy | Initiated | $68.00 | +57.8% | 07/27/2026 |
Michael Okunewitch Maxim Group | Buy | Reiterated | $50.00 | +16.1% | 06/23/2026 |
Christopher Chen Robert W. Baird | Buy | Maintained | $57.00 | +32.3% | 06/23/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $26.00 | -39.6% | 03/02/2026 |
Rudy Li Wolfe Research | Buy | Initiated | $25.00 | -42% | 02/23/2026 |
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.44 / -$0.55
-162.77%miss
arrow_downward
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 30.98M | 33.52M | 41.48M | 48.66M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 14.69M | 14.06M | 17.74M | 26.41M |
Operating expense | 45.67M | 47.58M | 59.22M | 75.08M |
Total operating expenses | 45.67M | 47.58M | 59.22M | 75.08M |
Operating income | -45.67M | -47.58M | -59.22M | -75.08M |
Other non operating income | -22.54M | -5.06M | -20.05M | -86.23M |
EBT including unusual items | -67.26M | -50.44M | -77.10M | -158.99M |
EBT excluding unusual items | -67.26M | -50.44M | -77.10M | -158.99M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -67.26M | -50.44M | -77.10M | -158.99M |
Net profit margin | - | - | - | - |
Earnings per share | -0.78 | - | - | -1.44 |
Interest and investment income | 2.26M | 3.49M | 3.46M | 3.59M |
Interest expense | -1.27M | -1.27M | -1.24M | -1.23M |
Net interest expenses | 988.00K | 2.22M | 2.21M | 2.35M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -45.66M | -47.57M | - | - |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
AI content may include mistakes. Learn more